#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Burkitt's lymphoma Netherton's syndrome Measles Marginal zone lymphoma refractory Non-small cell lung cancer Pleomorphic liposarcoma Homocystinuria Glioblastoma multiforme Congenital disorder of glycosylation Craniopharyngioma Proteus syndrome Head and neck cancer Autologous haematopoietic stem cell transplant Selective polysaccharide antibody deficiency Osteogenesis imperfecta More trials…

    Learn about Rare Diseases

    Osteosarcoma – Diagnostics Osteosarcoma recurrent – Treatment Medulloblastoma Choroid melanoma Usher’s syndrome Breast angiosarcoma metastatic – Basic Information Adrenogenital syndrome – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Chronic granulomatous disease – Life with Disease Osteosarcoma metastatic – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Promazine Hydrochloride Abiraterone Acetate M1P Dipotassium Salt Medi0618 Venlafaxine Hydrochloride Auto4 Oteracil DNL593 Lixudebart Vortioxetine Hydrobromide Amy109 Fadraciclib Daridorexant Potassium Chloride Raxtozinameran Adezunap Imetelstat Sodium Ltx-315 Alks 2680 Antiemetics And Antinauseants More therapies…

    Learn about Your Condition

    Meningococcal infection Agitation Gaucher's disease type I Factor IX deficiency Hypocalcaemia Kaposi's sarcoma Arthritis infective Psoriasis Eructation Dry mouth Muscular dystrophy Tinnitus Brain abscess Anal cancer metastatic Palmoplantar pustulosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliera di Padova

Azienda Ospedaliera di Padova

Via Nicolo' Giustiniani 2, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

    Recruiting

    3 1 1
    Investigated Diseases:
    • Left ventricular dysfunction
    • Cardiac failure
    Investigated Drugs:
    • Finerenone
    Austria Belgium Bulgaria Czechia Finland Germany +7

  • Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

    Recruiting

    3 1
    Investigated Diseases:
    • Short-bowel syndrome
    Investigated Drugs:
    • Glepaglutide
    Austria Belgium Czechia Denmark Estonia Finland +9

  • A study comparing prasinezumab with placebo for people with early-stage Parkinson’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Prasinezumab
    Austria Denmark France Germany Italy The Netherlands +3

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • A study of navenibart for long-term safety in patients with hereditary angioedema

    Recruiting

    3 1
    Investigated Drugs:
    • NAVENIBART
    Austria Bulgaria Czechia France Germany Hungary +5

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    Austria Czechia Denmark Finland France Germany +7

  • A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

    Recruiting

    4 1
    Investigated Drugs:
    • Danicamtiv
    Belgium Denmark France Hungary Italy The Netherlands +3

  • A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    • Waldenstrom’s macroglobulinaemia
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Zanubrutinib
    Italy
Previous Page
1 2 3 4 5 6 … 41
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!